Science

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

Elizabeth McKenna/X

Mar 24, 2025, 13:36

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

Elizabeth McKenna, Executive Director of Cancer Discovery at the American Association for Cancer Research, shared an article by Mansi Saxena, et al. on X:

“Now in Cancer Discovery:

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform:

Phase I Study in Patients with Solid & Hematological Malignancies in the Adjuvant Setting – by Mansi Saxena, Tom Marron, Philip Friedlander, Alex rubinsteyn, Bhardwaj Lab, et al.”

PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting.

Authors: Mansi Saxena, et al.

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

AACR alex rubinsteyn American Association for Cancer Research Bhardwaj Lab cancer Cancer Discovery Elizabeth McKenna fight against cancer Global fight against cancer hematological malignancies Mansi Saxena OncoDaily Oncology PGV001 Philip Friedlander Tom Marron

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action